NBTX VS BTMD Stock Comparison

Performance

NBTX
51/100

NBTX returned -7.36% in the last 12 months. Based on the other stocks in its sector with an average return of -7.41%, its performance is above average giving it a grade of 50 of 100.

BTMD
100/100

BTMD returned 12.38% in the last 12 months. Based on SPY's performance of -13.22%, its performance is above average giving it a score of 100 of 100.

Sentiment

NBTX
63/100

NBTX had a bullish sentiment score of 63.40% across Twitter and StockTwits over the last 12 months. It had an average of 30.90 posts, 5.83 comments, and 30.90 likes per day.

BTMD

"Sentiment" not found for BTMD

Volatility

NBTX
20/100

NBTX has had a lower than average amount of volatility over the last 12 months giving it a grade of 20 of 100.

BTMD
55/100

BTMD has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.

Technicals

NBTX

"Technicals" not found for NBTX

BTMD
14/100

BTMD receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

Earnings

NBTX

"Earnings" not found for NBTX

BTMD
46/100

BTMD has missed earnings 2 times in the last 20 quarters.

Profit

NBTX

"Profit" not found for NBTX

BTMD
48/100

Out of the last 11 quarters, BTMD has had 6 profitable quarters and has increased their profits year over year on 2 of them.

All score calculations are broken down here to help you make more informed investing decisions

Nanobiotix S.A. American Depositary Shares Summary

Nasdaq / NBTX

Healthcare

Biotechnology

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Biote Corp. Class A Common Stock Summary

Nasdaq / BTMD

Healthcare

Medical - Care Facilities

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

Power up your portfolio